Short answer
Xenon Pharmaceuticals Inc. (XENE) filed its Q1 2026 10-Q quarterly report on May 7, 2026 for the quarter ended Mar 31, 2026. Quarterly revenue was $0 (down 100.0% year over year) with net income of −$102M.
Q1 2026 key financials · XBRL
- Revenue
- $0
- −100.0% YoY
- Net income
- −$102M
- −57.3% YoY
- EPS (diluted)
- −$1.17
- −41.0% YoY
Source: XBRL data from the Xenon Pharmaceuticals Inc. (XENE) Q1 2026 10-Q on SEC EDGAR. USD.
Xenon Pharmaceuticals Inc. Q1 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Risk Factors
- Net loss $102.3 million and accumulated deficit $1,347.7 million as of March 31, 2026
- Funding runway expected at least 12 months, with additional capital potentially required sooner
- Azetukalner Phase 3 studies across epilepsy, major depressive disorder, and bipolar depression
- No prior Phase 3 or commercialization experience, increasing execution risk for azetukalner
- Canadian-dollar cash and expenses unhedged, exposing earnings to currency fluctuations
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Xenon Pharmaceuticals Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.